E-Leviate is a women’s health medical technology company developing innovative drug-delivery solutions for under-served urogenital conditions, including vaginal atrophy, genitourinary syndrome of menopause (GSM), pelvic organ prolapse (POP), urinary stress incontinence, and cystitis.

The company’s proprietary slow-release delivery platform is designed to provide sustained, targeted treatment, addressing limitations of existing therapies while supporting improved clinical outcomes and patient experience. 

Built on rigorous science and protected by strong intellectual property, E-Leviate’s technology integrates biomedical engineering with clinical insight to move beyond traditional treatment models. 

With trials progressing well and development nearing completion, E-Leviate is approaching market entry with a strong emphasis on clinical performance, patient outcomes, and usability in everyday practice. The company’s focus remains on delivering a reliable, evidence-based medical technology that meaningfully improves care in women’s health.

E-Leviate is the trading name of E-Leviate Pharma Ltd.

E-Leviate

Org chart

Teams

Offices